Abstract
Sodium–glucose cotransporter 2 (SGLT2) inhibitors offer attractive metabolic and cardiorenal benefits for patients with type 2 diabetes, but are associated with a number of safety issues. A recent study documented that SGTL2 inhibition indirectly triggers the FGF23/1,25-dihydroxyvitamin D/parathyroid hormone axis, which may contribute to adverse effects on bone health.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, N.I.H., Intramural
MeSH terms
-
Bone Demineralization, Pathologic / chemically induced*
-
Bone Density / drug effects
-
Canagliflozin / adverse effects
-
Fibroblast Growth Factor-23
-
Fibroblast Growth Factors / blood*
-
Fractures, Bone / chemically induced*
-
Humans
-
Parathyroid Hormone / blood
-
Phosphorus / blood
-
Sodium-Glucose Transporter 2 Inhibitors / adverse effects*
-
Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
-
Vitamin D / analogs & derivatives
-
Vitamin D / blood
Substances
-
Parathyroid Hormone
-
Sodium-Glucose Transporter 2 Inhibitors
-
Canagliflozin
-
Vitamin D
-
Phosphorus
-
Fibroblast Growth Factors
-
1,25-dihydroxyvitamin D
-
Fibroblast Growth Factor-23